Rituximab
- PDF / 169,308 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 88 Downloads / 177 Views
1 S
Infusion-related reaction, headaches and worsening of hearing loss: 4 case reports In an analysis of 263 patients, 4 patients [ages and sexes not stated] were described, who developed infusion-related reaction, headaches or worsening of hearing loss during treatment with biosimilar rituximab for rheumatoid arthritis (RA) [dosages and duration of treatment to reactions onsets not stated; not all outcomes stated]. The patients, who had RA, had been receiving treatment with originator rituximab. Later, they were switched to biosimilar rituximab infusion. However, 4 patients developed adverse events in the form of infusion-related reaction (2 patients), headaches (1 patient) and worsening of hearing loss (1 patient). One of the 2 patients, who developed infusion-related reaction, was successfully re-treated with originator rituximab, and the second patient was pending for change in therapy. The patient, who experienced headaches, recovered by switching to originator rituximab. Melville A, et al. Clinical responses, B cell depletion and treatment outcomes following rituximab biosimilar switch in RA: Is there value in switching back?. Rheumatology 803507315 59 (Suppl. 2): ii24 (plus poster) abstr. P12, Apr 2020. Available from: URL: http://doi.org/10.1093/rheumatology/keaa111.011 [abstract]
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
